Calliditas Therapeutics-ADRCALT
13F holders, Q1 2024 (March 31)19holders
2famous investors
$21.58avg. 13F price*
At the end of Q1 2024, 19 institutions reported holding Calliditas Therapeutics-ADR (CALT) in their 13F filings. The largest holders were BVF Inc. ($16.2M), Deutsche Bank AG ($1.1M) and Ironwood Investment Management LLC ($536K). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Paul Tudor Jones (0.0% of Tudor Investment Corporation's portfolio).
- Company
- Calliditas Therapeutics-ADR
- CUSIP
- 13124Q106
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $2K |
| Exits | 3 | $42K |
Ownership 19 holders
| BVF Inc. | 0.45% | No change | 750,000 | $16.2M |
| Deutsche Bank AG | 0.00% | No change | 50,550 | $1.1M |
| Ironwood Investment Management LLC | 0.26% | Add +0.3% | 25,511 | $536K |
| Citadel Advisors | 0.00% | Add +1664.7% | 14,594 | $316K |
| Susquehanna International Group, LLP | 0.00% | Add +9.2% | 10,277 | $222K |
| Morgan Stanley | 0.00% | Add +894.4% | 5,986 | $126K |
| Federation des caisses Desjardins du Quebec | 0.00% | Add +60.4% | 3,985 | $84K |
| Wells Fargo & Company | 0.00% | Add +150.7% | 3,760 | $79K |
| Optiver Holding B.V. | 0.00% | Add +158.6% | 2,534 | $55K |
| Osaic Holdings, Inc. | 0.00% | Reduce -5.8% | 1,104 | $23K |
| Bank of America Corp. | 0.00% | Add +232.9% | 1,042 | $22K |
| Planning Capital Management Corp | 0.01% | No change | 877 | $18K |
| Simplex Trading, LLC | 0.00% | Add +107.1% | 671 | $14K |
| Rhumbline Advisers | 0.00% | No change | 164 | $4K |
| Colonial Trust Advisors | 0.00% | No change | 105 | $2K |
| Qube Research & Technologies Ltd | 0.00% | No change | 72 | $2K |
| Tudor Investment Corporation | 0.00% | New | 65 | $1K |
| CVA Family Office, LLC | 0.00% | New | 45 | $945 |
| Missouri Trust & Investment Co | 0.00% | No change | 35 | $735 |
"% of holder's portfolio" is CALT's weight in each manager's 13F, not the share of Calliditas Therapeutics-ADR the manager owns.